Home Neoplasma 2014 Neoplasma Vol.61, No.1, p.35-40, 2014

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.61, No.1, p.35-40, 2014

Title: Prognostic implication of TIM-3 in clear cell renal cell carcinoma
Author: J. Yuan, B. Jiang, H. Zhao, Q. Huang


Clear cell renal carcinoma (ccRCC) is the most common tumor of the kidney.in adults. The prognosis of ccRCC remains unsatisfactory. Recently, T cell immunoglobulin mucin-3 (TIM-3), a novel transmembrane protein, has been implicated in tumor biology. Its role in ccRCC remains unkonwn. The aim of this study was to investigate the roles of TIM-3 as a prognostic marker in patients with ccRCC.TIM-3 protein expression was determined by immunohistochemistry and Western blot from 137 ccRCC tumor samples and adjacent normal renal tissues. We performed also the cell proliferation assay using 3-(4,5-dimethylthiazol -2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay.

The effects of small interfering RNA (siRNA)-mediated knockdown of TIM-3 (TIM-3 siRNA) in two human ccRCC cell lines were evaluated. TIM-3 expression was higher in ccRCC tissue than in the adjacent normal renal tissue (P<0.001).

High TIM-3 expression was an independent predictor of both cancer-specific survival and progression-free survival. TIM-3 protein was expressed in both ccRCC cell lines. Knockdown of TIM-3 suppressed the proliferation and invasion capacity of ccRCC cell lines.TIM-3 expression was associated with poor prognosis in ccRCC. Taken together, TIM-3 is a potential prognostic marker in ccRCC.

Keywords: TIM-3; clear cell renal cell carcinoma; prognosis; marker
Published online: 19-Sep-2013
Year: 2014, Volume: 61, Issue: 1 Page From: 35, Page To: 40

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.